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Abst rac t
Familial partial lipodystrophy (FPLD) belongs to the family
of laminopathies – disorders associated with mutation in the
lamin A/C gene (LMNA). FPLD is characterized by loss of
subcutaneous adipose tissue from the limbs, trunk and
buttocks, with its concomitant accumulation on the face, neck
and intra-abdominal region, and by metabolic disorders.
We present the first Polish family with FPLD confirmed
genetically. A 34-year-old woman admitted with myalgia and
cushingoid appearance was found to have a round face with
double chin, neck bump, and loss of fat on extremities.
Diagnostic tests revealed impaired glucose tolerance and
increased levels of liver enzymes, and ultrasonography
revealed hepatic steatosis. Her 9-year-old daughter presented
a similar phenotype, but no fat loss. A genetic test revealed
the presence of a heterozygous LMNA gene mutation:
c.1445G>A, consistent with the “hot spot” for FPLD.
Treatment with metformin to improve insulin resistance and
address the diabetes proved successful.
Key words: familial partial lipodystrophy (FPLD), LMNA,
lamin A/C, laminopathies.
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CASE REPORT/OPIS PRZYPADKU
St reszczenie
Rodzinna czêœciowa lipodystrofia (familial partial lipody -
strophy – FPLD) nale¿y do laminopatii – chorób zwi¹zanych
z mutacjami genu laminy A/C (LMNA). Charakteryzuje siê
utrat¹ podskórnej tkanki t³uszczowej na koñczynach, tu³owiu
i poœladkach z jednoczesnym jej przemieszczeniem na twarz,
szyjê i do przestrzeni wewn¹trzbrzusznej oraz zaburzeniami
metabolicznymi. Prezentujemy pierwsz¹ polsk¹ rodzinê
z genetycznie potwierdzon¹ FPLD. Trzydziestoczteroletnia
chora zosta³a przyjêta do szpitala z powodu bólów miêœni oraz
cushingoidalnego wygl¹du. Klinicznie stwierdzono zaokr¹gle-
nie twarzy, podwójny podbródek, nagromadzenie tkanki
t³uszczowej na karku oraz zanik tkanki t³uszczowej na
koñczynach. Badania wykaza³y nieprawid³ow¹ tolerancjê glu-
kozy i zwiêkszon¹ aktywnoœæ enzymów w¹trobowych, zaœ
USG – cechy st³uszczenia w¹troby. Dziewiêcioletnia córka
chorej prezentuje podobieñstwo fenotypowe do matki, jed-
nak¿e obecnie bez zaniku tkanki t³uszczowej. W badaniu
genetycznym u chorej i jej córki stwierdzono heterozygotyczn¹
substytucjê w genie LMNA: c.1445G>A (p.Arg482Gln),
która znajduje siê w miejscu „hot spot” dla FPLD w 8. ekso -
nie. Chorej podano metforminê w celu leczenia insulino -
opornoœci i zaburzeñ gospodarki wêglowodanowej.
S³owa kluczowe: rodzinna czêœciowa lipodystrofia, LMNA,
lamina A/C, laminopatie.
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Introduction
Familial partial lipodystrophy (FPLD),
OMIM#151660, is a rare human disorder characterized
by partial loss of subcutaneous adipose tissue on the limbs,
trunk and buttocks and a concomitant accumulation
thereof on the face, neck and intra-abdominal region, this
being associated with insulin-resistant diabetes mellitus,
hypertriglyceridaemia and hormonal imbalance. The
disease onset is usually at puberty, women being more
severely affected. Complications of polymetabolic
syndrome, such as premature atherosclerosis or acute
pancreatitis, may be capable of influencing lifespan [1-5].
FPLD belongs to the group (and accounts for about 8%)
of the so-called laminopathies, these being rare inherited
human diseases affecting skeletal muscle, peripheral nerves
and adipose tissue, or causing multisystemic syndromes,
including premature aging [6]. Laminopathies are
associated with mutations in the LMNA gene that encodes
the nuclear envelope proteins lamin A and lamin C.
Nuclear lamins are members of the intermediate filament
(IF) family of proteins and are present in differentiated
cells. Like all IF proteins, they consist of an alpha-helical
rod domain flanked by a non-helical N-terminal head and
C-terminal tail domains. They form the main component
of nuclear lamina, responsible for the maintenance of
nuclear structure, for chromatin organization and gene
expression and for influencing cell development,
differentiation and apoptosis. Apart from FPLD,
laminopathies encompass a wide spectrum of different
human disorders, affecting skeletal muscles (Emery-
Dreifuss dystrophy, EDMD-AD and EDMD-AR;
limb-girdle dystrophy 1B, LGMD1B) [7], heart muscle
(dilated cardiomyopathy with conduction disturbances,
DCM) [8] or peripheral nerves (Charcot-Marie-Tooth
2B, CMT2B) [9], or generating multisystemic diseases
bearing features of premature aging, i.e. mandibuloacral
dysplasia (MAD) [10], Hutchinson-Gilford progeria
(HGPS) [11,12], atypical Werner syndrome and
restrictive dermatopathy (RD) [13].
We describe here two Polish patients, a mother and
daughter, who presented typical symptoms of FPLD,
as dependent on the heterozygous LMNA mutation
Arg482Gln.
Case report
A thirty-four-year-old woman presented to the
neuromuscular outpatient clinic complaining of changes
in her appearance, i.e. moon-like face, thick neck, slim
legs and arms with pronounced muscle profile and
myalgia. The symptoms were noticed at first when she
was about 20, but she visited her primary care physician
only when myalgia occurred; then she was 32. At the
time in question she also complained of chronic
headaches and depression. While she was suspected of
having Cushing syndrome, the hormonal tests did not
confirm this diagnosis. On the basis of increased levels
of AST, ALT and GGT, hepatopathy was diagnosed,
but viral hepatitis was excluded. Although the woman
Fig. 1. Patient with familial partial lipodystrophy (FPLD). Note loss of subcutaneous adipose tissue on limbs resulting in prominent muscles, plus concomitant fat accu-
mulation on face and neck
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has two children, her first, third and fifth pregnancies
miscarried. In addition, she has had irregular menstrual
periods since adolescence.
On physical examination we found a round face with
double chin and neck bump, and loss of subcutaneous fat
on arms and legs, resulting in apparent musculature 
(Fig. 1). Muscle strength and tendon jerks were normal.
No sensory disturbances were detected. Clinical
examination of the patient’s mother and two children was
carried out, the mother proving asymptomatic on
neurological examination. The single abnormality in the
8-year-old son was a high palate arch. The 9-year-old
daughter presented a similar phenotype to her mother as
regards general appearance and posture, though there had
been no fat loss at the time of the examination (Fig. 2).
Diagnostic tests
Laboratory tests revealed increased levels of liver
enzymes, i.e. AST – 85 U/L (N: 5-40); ALT – 
111 U/L (N: 7-56) and GGTP – 70 U/L (N: 7-50);
as well as impaired glucose tolerance: fasting glucose
109 mg%, 120 min – 167 mg%; high levels of insulin:
fasting – 61.24 μIU/mL, 120 min – 92.24 μIU/mL
(N: 2.1-22); peptide C: fasting – 7.88 ng/mL, 120 min
– 10.62 ng/mL (N: 0.48-3.3); and HbA1c: 6.6% (N:
4.5-6.5); and slight dyslipidaemia: total cholesterol: 
90 mg/dL (N: 120-200), HDL cholesterol – 32 mg/dL
(N: > 40). Serum CK, thyroid hormones and cortisol
proved normal, as did EMG and ENG. The patient
had two muscle biopsies done: from the brachial biceps
(in another hospital) and from the femoral quadriceps.
The first biopsy revealed normal muscle morphology,
but in the second biopsy there was only adipose 
tissue in the specimen. Ultrasonography revealed
hepatomegaly with hepatic steatosis. Computed
tomography scans of the neck and upper mediastinum
were normal, and no abnormalities were revealed by
cardiological evaluation (ECG, echocardiography). The
patient is under the care of a diabetologist and she has
been treated successfully with metformin and diet –
glucose tolerance is improved. Unfortunately, sometimes
the patient is not fully compliant with the treatment
schedule, although possible complications of metabolic
Fig. 2. Pedigree of family affected by familial partial lipodystrophy (FPLD), showing autosomal dominant trait of inheritance
II:3
III:2
IV:1 IV:2
proband
male
female
LMNA htz 1445G > A (p.Arg482GIn)
miscarriage
II:3, III:2, IV:1, IV:2 – genetic test done
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syndrome were discussed with her. The affected child
of the patient had glucose and liver enzyme testing done
– the results were within the normal range.
Genetic analysis
Once written informed consent had been received,
we performed genetic analysis in the proband, her
mother and two children. Genomic DNA was extracted
from peripheral blood lymphocytes. All 12 exons of
LMNA and exon-intron boundaries were amplified by
PCR, sequenced using the Big Dye Terminator
Sequencing Ready Reaction kit (Applied Biosystems),
and analysed on an ABI PRISM 373 fluorescent DNA
sequencer (Applied Biosystems). Primer sequences and
PCR protocols are available upon request.
Direct DNA sequencing revealed a heterozygous
missense mutation at codon 482 (c.1445G>A),
resulting in arginine-to-glutamine change in the patient
(III:2) and her daughter (IV:1). The mutation was not
found in the second healthy child (IV:2), or in the
patient’s mother (II:3) (Fig. 3).
Discussion
As a disorder, lipodystrophy, i.e. a loss of sub -
cutaneous fat, can be acquired (more commonly) or
inherited (less commonly), generalized or partial [14].
Although genetically conditioned Dunnigan familial
partial lipodystrophy is a rare lipodystrophy, its clinical
presentation is well described and the consequences of
metabolic complications are relevant as to general health
status and lifespan.
Patients with FPLD have normal fat distribution
during childhood, abnormalities only occurring in
adolescence. This is probably the reason for the absence
of lipodystrophy in the patient’s 9-year-old daughter, in
whom we found the same LMNA mutation. Our
patient’s phenotype, i.e. fat atrophy on the extremities,
buttocks and thorax, with accumulation thereof on the
face, neck and axillae, and in the pubic region, suggested
familial partial lipodystrophy [1]. Acanthosis nigricans,
polycystic ovaries and hypertension can also occur in such
patients, though our patient did not have them. Our
patient’s hepatomegaly with hepatic steatosis found on
ultrasonography, plus slightly increased ALT and AST,
are consistent with observations in FPLD patients
described in the literature [15]. The muscle pathology
in FPLD can manifest as severe myalgia, and this
symptom was present in our patient. Recent studies have
shown that FPLD patients may display hypertrophy of
type 1 and 2 muscle fibres, as well as non-specific
changes in muscles, and myelin swellings at paranodal
regions. A recent hypothesis holds that the myopathy and
neuropathy in FPLD may be associated with interference
of lipodystrophy-associated mutation with Smad
signalling [16]. It is not possible to assess skeletal muscle
morphology in our patient as the specimen from the
femoral quadriceps contained only adipose tissue,
although in the previous biopsy from the brachial biceps,
done in another hospital, no abnormalities were found
on light microscopy. Lipodystrophy may be accompanied
by heart pathology, i.e. septum hypertrophy, atheromatosis
in coronary vessels and conduction disturbances [17].
Our additional tests showed no heart abnormalities in
our patient at the time of examination, though we may
not exclude them in future. The abnormal balance as
regards female hormones may be responsible for the
irregular periods, which are frequently observed in
women with Dunnigan lipodystrophy, who may also
experience infertility and miscarriages.
Results of diagnostic tests in FPLD reveal insulin
resistance, hyperinsulinaemia, hyperglycaemia, hyper -
triglyceridaemia and low HDL cholesterol. The earliest
abnormality is hyperinsulinaemia, which may initially
compensate for insulin resistance. Dyslipidaemia also
precedes the onset of impaired glucose tolerance and
diabetes and it seems to be related to the extent of fat
loss [18]. Diabetes arises in the third decade of life, the
predisposing factors being higher BMI, higher body fat
content and an elevated fasting level of triglycerides
[4,5]. At diagnosis, our patient had impaired glucose
tolerance with insulin resistance, and slight dyslipidaemia
with a decreased HDL cholesterol level. We did not
expect serum lipid abnormalities in the patient’s
daughter, who was 9 years old at the time of examination.
Dyslipidaemia appears later, when fat loss is evident, i.e.
in adolescence, and then regular control of metabolic
parameters is recommended.
Typical lamin-dependent FPLD is very rare in the
general population, estimated to be present with
a frequency of 1 : 10 000 000. The majority of patients
described in the literature originate from Europe,
though this is the first report of genetically confirmed
FPLD in the Polish population. Among the more than
320 LMNA mutations described in the UMD-LMNA
database and confirmed as causal factors in FPLD,
nearly 90% affect exon 8 of the LMNA gene. The
majority of these are in the “hot spot”, which includes
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codon 482. The most frequent substitutions are
c.1444C>T (p.Arg492Trp) and c.1445G>A
(p.Arg482Gln), accounting for 103 and 75 of 327
described cases, respectively. [19,20] Noting the
existence of the LMNA “hot spot” for FPLD, we began
our genetic screening in the patients with analysis of exon
8 of LMNA, in this way confirming the presence of
nucleotide substitution at exactly the expected location,
i.e. c.1445G>A (p.Arg482Gln). We found no muta -
tions in the remaining LMNA exons.
Fig. 3. Sequencing of the direct stand of LMNA exon 8 revealing heterozygous point mutation 1445G>A (p.Arg482Gln) in proband (III:2), and the same 
heterozygous point mutation in the patient’s daughter (IV:1)
II:3
III:2
IV:1 IV:2
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The patient described presents typical symptoms of
familial partial lipodystrophy. Impaired glucose tolerance
and insulin resistance are being treated in line with
recommendations. Detection of the LMNA hetero -
zygous mutation c.1445G>A in the patient’s daughter
allows for earlier diagnosis and for treatment of the
metabolic syndrome while the sufferer is still in early
adulthood.
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